We have located links that may give you full text access.
Journal Article
Review
Safety considerations when treating myelofibrosis.
Expert Opinion on Drug Safety 2016 September
INTRODUCTION: Myelofibrosis (MF) is a clonal disorder leading to marrow fibrosis, cytopenias and extramedullary haematopoiesis.
AREAS COVERED: Generic management of MF with a specific focus on the efficacy and safety profile of the Janus Kinase (JAK)1/JAK 2 kinase inhibitor, ruxolitinib (Novartis Pharmaceuticals, Basel, Switzerland), will be discussed. This agent has manageable haematological side effects and possesses both beneficial and potentially detrimental immunosuppressive effects. Multiple JAK inhibitors are in various stages of development but some have been withdrawn due to unexpected toxicities such as the occurrence of Wernicke's encephalopathy (Fedratinib; Sanofi, Paris). Traditional therapies such as hydroxycarbamide, interferon, immunomodulatory drugs and androgens will also be discussed.
EXPERT OPINION: Therapeutic options in MF have expanded with the introduction of JAK inhibitors. Ruxolitinib benefits many patients with symptomatic MF. Other JAK inhibitors such as momelotinib may have the additional benefit of alleviating anaemia. Unfortunately, there is no current JAK inhibitor option for patients with severe thrombocytopenia as pacritinib was recently put on clinical hold due to adverse events. Careful consideration needs to be given towards optimal management of patients who lose their response/are resistant to JAK inhibitor therapies and those with a high risk mutational status but lower risk prognostic score.
AREAS COVERED: Generic management of MF with a specific focus on the efficacy and safety profile of the Janus Kinase (JAK)1/JAK 2 kinase inhibitor, ruxolitinib (Novartis Pharmaceuticals, Basel, Switzerland), will be discussed. This agent has manageable haematological side effects and possesses both beneficial and potentially detrimental immunosuppressive effects. Multiple JAK inhibitors are in various stages of development but some have been withdrawn due to unexpected toxicities such as the occurrence of Wernicke's encephalopathy (Fedratinib; Sanofi, Paris). Traditional therapies such as hydroxycarbamide, interferon, immunomodulatory drugs and androgens will also be discussed.
EXPERT OPINION: Therapeutic options in MF have expanded with the introduction of JAK inhibitors. Ruxolitinib benefits many patients with symptomatic MF. Other JAK inhibitors such as momelotinib may have the additional benefit of alleviating anaemia. Unfortunately, there is no current JAK inhibitor option for patients with severe thrombocytopenia as pacritinib was recently put on clinical hold due to adverse events. Careful consideration needs to be given towards optimal management of patients who lose their response/are resistant to JAK inhibitor therapies and those with a high risk mutational status but lower risk prognostic score.
Full text links
Related Resources
Trending Papers
Consensus Statement on Vitamin D Status Assessment and Supplementation: Whys, Whens, and Hows.Endocrine Reviews 2024 April 28
The Tricuspid Valve: A Review of Pathology, Imaging, and Current Treatment Options: A Scientific Statement From the American Heart Association.Circulation 2024 April 26
British Society of Gastroenterology guidelines for the management of hepatocellular carcinoma in adults.Gut 2024 April 17
Interstitial Lung Disease: A Review.JAMA 2024 April 23
Ventilator Waveforms May Give Clues to Expiratory Muscle Activity.American Journal of Respiratory and Critical Care Medicine 2024 April 25
Systemic lupus erythematosus.Lancet 2024 April 18
Acute Kidney Injury and Electrolyte Imbalances Caused by Dapagliflozin Short-Term Use.Pharmaceuticals 2024 March 27
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app